Results 181 to 190 of about 103,359 (263)

Exploring the α-Glucosidase Inhibitory Activity of Bioactive Compounds from <i>Persicaria odorata</i> (Lour.) Extracts via Integrated In Vitro and In Silico Studies. [PDF]

Int J Mol Sci
Subhan M, Sanachai K, Nutho B, Ratha J, Siriparu P, Datham S, Bangthong B, Padumanonda T, Sungthong B, Puthongking P.   +9 more
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Content Differences of Active Ingredients in Different Flower Colors of <i>Carthamus tinctorius</i> L. and Their α-Glucosidase Inhibitory Effects Based on Network Pharmacology and Molecular Docking. [PDF]

Curr Issues Mol Biol
Huang F, Zhao W, Wang S, Li J, Zeng L, Zhu J.   +5 more
europepmc   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

Pharmacological insights into the antidiabetic potential of <i>Rosa hybrida</i> Hort. flowers based on enzyme inhibition and computational analysis. [PDF]

Toxicol Rep
Sutrisno E, Susanti R, Sodik JJ, Akbar NH, Fakih TM, Adlina S, Amin S.   +6 more
europepmc   +1 more source

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar, Luxcia Kugathasan, Manon Girard, Michael J. Davies, David Z. I. Cherney   +4 more
wiley   +1 more source

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source

In silico modeling and in vitro evaluation of antidiabetic potential of exopolysaccharides from Brassicaceae root endophytic bacteria. [PDF]

J Genet Eng Biotechnol
Kusmiati K, Nurkanto A, Fanani A, Mamangkey J, Nurcahyanto DA, Pasaribu KM, Ramadhani I, Putri AL, Afiati F, Agustini NWS, Irawan H, Priadi D, Adalina Y, Taufik M, Mandasari S, Rohadi H.   +15 more
europepmc   +1 more source

Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Glycated albumin (GA), the product of nonenzymatic glycation of serum albumin, reflects the mean glucose levels over the preceding approximately 2 weeks, bridging the gap between daily self‐monitoring of blood glucose and the roughly 3‐month window covered by glycated hemoglobin (HbA1c) measurement.
Masakazu Aihara, Naoto Kubota
wiley   +1 more source